Clinical trials: Prostatic Neoplasms
Oligo-metastatic Prostate Carcinoma
Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer
The existing large prospective study demonstrates the benefits of primary radiotherapy in patients with low-volume oligo-metastatic prostate cancer (OMPC), and there is also more evidence of the benefits of local…
- Trial name
- NCT06198387
- Testing
- hormone and RT, ADT combined with abiraterone
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Changhai Hospital
Prostate Cancer
Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer
RATIONALE: The use of nutritional supplements, such as selenium, may stop prostate cancer from growing. Internal radiation, such as brachytherapy, uses radioactive material placed directly into or near a tumor to kill tumor…
- Trial name
- NCT00217516
- Testing
- selenium
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Urothelial Cancer, Bladder Cancer
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Background: Tumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancers that occur along the genitourinary (GU) tract are rare.
- Conditions
- Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms
- Trial name
- NCT04923178
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Prostate Cancer
Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer
Evaluation of patient reported outcomes (PRO) / QoL regarding typical ailments in real-life patients with bone metastases treated with osteoprotective agents.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Metastases
- Trial name
- PROBone (NCT02410044)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- iOMEDICO AG
Bone Metastases, Castrate-resistant Prostate Cancer
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
This study is being done to help researchers understand more about prostate cancer that has spread to the bones by using the newest magnetic resonance imaging (MRI) techniques and to better understand the effect of an…
- Conditions
- Bone Metastases, Castrate-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01599793
- Testing
- cabozantinib, laboratory biomarker analysis, magnetic resonance imaging
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Chicago
Prostate Cancer
Robotic Surgery After Focal Ablation Therapy
The toxicity of traditional prostate cancer therapies including radical surgery and external beam radiation is well known. This has prompted a move towards focal therapy where only the cancerous part of the prostate is treated.
- Trial name
- RAFT (NCT03011606)
- Testing
- Robotic Surgery
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Queen Mary University of London
Prostate Cancer
A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone
This study investigates neoadjuvant TAK-700 orteronel for 6 months prior to prostatectomy. The three year biochemical free survival is the primary endpoint.
- Trial name
- NEPTUNE (NCT03211052)
- Testing
- TAK-700 and LHRH agonist, prostatectomy
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Centre of Experimental Medicine
Metastatic Castration-resistant Prostate Cancer
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
This is a pilot study to assess the safety and measure image-based absorbed dose of 177Lu-PSMA-EB-01, a new PSMA-specific radiopharmaceutical, in patients with metastatic castration resistant prostate cancer (mCRPC) who will…
- Trial name
- NCT05613738
- Testing
- 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01, 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01, 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Peking Union Medical College Hospital
Prostate Cancer
Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer
In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for participants with…
- Trial name
- NCT07548164
- Testing
- NanoKnife System, Stereotactic Body Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 224 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer of Prostate
Investigation of Three Biomarkers for the Detection of Prostate Cancer
GlycoScore Dx Limited, a diagnostics company based in the United Kingdom have identified three glycoproteins, that showed promise as biomarkers of prostate cancer in initial validation studies.
- Trial name
- NCT06554587
- Testing
- Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Medtechtomarket Consulting Ltd
Prostate Cancer
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
The purpose of this study is to look at the effects (good and bad) of the combination of docetaxel and carboplatin for patients who have progressive prostate cancer after chemotherapy with drugs such as docetaxel.
- Trial name
- NCT00134706
- Testing
- Docetaxel, Carboplatin
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Castration-resistant Prostate Cancer
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]).
- Trial name
- NCT06691984
- Testing
- Xaluritamig, Abiraterone, Enzalutamide
- Where
- 164 sites in United States, Australia and 20 more
- Volunteers
- 707 people
- Sponsor
- Amgen
Advanced or Metastatic Solid Tumors, Breast Cancer
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
- Trial name
- NCT06257758
- Testing
- VIO-01
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Valerio Therapeutics
Metastatic Prostate Cancer
Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy
Prostate cancer is the first cancer in men. The treatment of metastatic prostate cancer with chemotherapy is based on the intravenous administration of docetaxel chemotherapy.
- Trial name
- HypProMet (NCT04533958)
- Testing
- HYPNO VR® device
- Where
- 6 sites in France, Portugal
- Volunteers
- 53 people
- Sponsor
- Saint-Gregoire Private Hospital Center
Prostate Cancer
Focal Therapy for Localized Prostate Cancer
This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care.
- Trial name
- NCT06270043
- Testing
- Focal Therapy
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Prostate Cancer, Prostate Carcinoma
The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation
This is a multi-center, single-arm, prospective study to assess the efficacy and safety of Olaparib in men with newly diagnosed metastatic castration-resistant prostate cancer (mCRPC) who carried homologous recombination repair…
- Conditions
- Prostate Cancer, Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- PROspect (NCT05262608)
- Testing
- Olaparib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer, Prostate Cancer
Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome
Exposure to radiation can impact immune cells that are present in the blood, such as lymphocytes. It is hypothesized that larger radiation fields and/or longer courses of radiation, result in greater decrease in immune cells.
- Trial name
- NCT03383107
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Weill Medical College of Cornell University
Prostatic Neoplasms
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
A single-arm, open-label Phase II clinical trial to evaluate the effect of G-202 on the perfusion and volume of the prostate using non-invasive multiparametric prostate magnetic resonance imaging (mpMRI).
- Trial name
- NCT02381236
- Testing
- G-202
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- GenSpera, Inc.
Prostate Cancer
Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
The purpose of this study is to assess the safety and activity of DC/PC3, a dendritic cell vaccine used as immunotherapy for prostate cancer.
- Trial name
- NCT00345293
- Testing
- autologous dendritic cell vaccine (DC/PC3)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Rockefeller University
Localized T1-T2 Prostate Cancer
SpaceOAR System RWS in China
This study aims to evaluate the safety and performance of SpaceOAR System when it is used to create space between the rectum and prostate in men undergoing radiotherapy for localized T1-T2 prostate cancer in China via collecting…
- Trial name
- NCT05407714
- Testing
- SpaceOAR Treatment
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation